Neflamapimod Phase 2a Data in Primary Progressive Aphasia Show Exposure-Linked NfL Decline Isabella Ciccone, MPH

Published Date: 21 Nov 2026

In a phase 2a trial presented at CTAD 2026, neflamapimod kept plasma NfL stable in nonfluent variant primary progressive aphasia over 24 weeks.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Three out of ten breast cancers detected between screenings, study finds

2.

Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments

3.

Where Did This Very Painful Gluteal Mass Come From?

4.

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.

5.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot